SCHEMBL7154752

SCHEMBL7154752

C=CCOC(=O)CNCCNC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
GAA P10253 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 3/20 0.39
CA2 P00918 3/20 0.39
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
EPHX1 P07099 1/20 0.39
TSHR P16473 1/20 0.36
MALT1 Q9UDY8 1/20 0.34
IDO1 P14902 1/20 0.34
ADRB2 P07550 1/20 0.34
HTR1A P08908 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22175642 0.92 MAOA (0.55) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL5136229 0.88 SMN1; SMN2 (0.50) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL1276792 0.85 TDP1 (0.49) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL21738506 0.84 SMN1; SMN2 (0.47) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL13471245 0.82 SMN1; SMN2 (0.46) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL432412 0.82 MAOA (0.51) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL7530750 0.81 MAOA (0.57) MAOAMAOBTDP1GAAMEN1
Hydrochloric Acid SCHEMBL5158594 0.81 MAOA (0.50) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL18747980 0.81 MAOA (0.43) MAOAMAOBSMN1; SMN2TDP1GAA
SCHEMBL1631203 0.80 MAOA (0.44) MAOAMAOBSMN1; SMN2TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207804-A1 Modified peptide nucleic acids ISIS PHARMACEUTICALS, INC. 2003-11-06 US disclosed
WO-2002097134-A2 MODIFIED PEPTIDE NUCLEIC ACID ISIS PHARMACEUTICALS, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207804-A1 Modified peptide nucleic acids NGLY1, PARN, NPPA MAOA 4491/4885MAOB 4231/4885SMN1; SMN2 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.